Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
44 results
  • Breast Cancer

18-084          Phase II

A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel, Oral Paclitaxel) Compared to IV Paclitaxel in Patients with Recurrent or Metastatic Breast Cancer (View details on clinicaltrial.gov)

  • Endometrial Cancer, Breast Cancer, Bladder Cancer, Ovarian Cancer

17-392          Phase I

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Ovarian Cancer, Lung Cancer, Endometrial Cancer, Breast Cancer

16-393          Phase I

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors (View details on clinicaltrial.gov)

  • Metastatic/Advanced Cancer, Breast Cancer, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma

17-334          Phase I

A Phase 1, Open-Label, Multicenter, Dose Escalation Study or MRNA-2416, A Lipid Nanoparticle Encapsulated MRNA Encoding Human OX4OL, For Intratumoral Injection to Patients with Advanced Malignancies (View details on clinicaltrial.gov)

  • Breast Cancer

17-371          Phase II

A Phase 1/2 study for the safety, efficacy, pharmacokinetic and pharmacodynamics evaluation of SAR439859, administered orally as monotherapy, then in combination with palbociclib in postmenopausal women with estrogen receptor-positive advanced breast cancer (View details on clinicaltrial.gov)

  • Head and Neck Cancer, Breast Cancer, Kidney Cancer, Lung Cancer, Merkel Cell Carcinoma

18-051          Phase I

A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors (View details on clinicaltrial.gov)

  • Breast Cancer

17-328          Phase I

A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination with Pembrolizumab in HLA-A2+ Patients with Metastatic Triple Negative Breast Cancer (TNBC) (View details on clinicaltrial.gov)

  • Breast Cancer, Lung Cancer

19-881          Phase I

A Phase 1b, Multicenter, Two-Part, Open-Label study of Trastuzumab Deruxtecan, and Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination with Pembrolizumab, an Anti-PD-1 Antibody, in Subjects with Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (NSCLC) (View details on clinicaltrial.gov)

  • Breast Cancer

19-578          Phase II

A phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized Triple-Negative Breast Cancer (NeoSTAR) (View details on clinicaltrial.gov)

  • Breast Cancer

19-055          Phase I

A Phase I Study of Niraparib Administered Concurrently with Postoperative RT in Patients with Triple Negative Breast Cancer with an Incomplete Pathologic Response (View details on clinicaltrial.gov)

Showing 1 - 10 of 44 results